| Literature DB >> 34592898 |
Wenbo Yang1,2, Peng Liu2, Yuling Zheng2, Zhongtian Wang1, Wenhua Huang2, Hua Jiang2, Qingyu Lv2, Yuhao Ren2, Yongqiang Jiang2, Liping Sun3.
Abstract
Urinary tract infection (UTI) is a common infectious disease. Urinary tract pathogenic Escherichia coli (UPEC) is the main cause of UTIs. At present, antibiotics are mainly used for the treatment of UTIs. However, with the increase of drug resistance, the course of the disease is prolonged. Therefore, identifying the receptors and signal pathways of host cells and tissues will further our understanding of the pathogenesis of UTIs and help in the development of new drug treatments. We used two public microarray datasets (GSE43790, GSE124917) in the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) between UTI and normal cell samples. A functional analysis based on Gene Ontology (GO) data, a pathway enrichment analysis based on Kyoto Encyclopedia of Genes and Genomes (KEGG) data and a protein-protein interaction analysis identified the main potential biomarkers and verified them in animal tissues. A total of 147 up-regulated genes and 40 down-regulated genes were identified. GO enrichment analysis showed that these functional changes relate to the terms response to lipopolysaccharide, regulation of cytokine production, and regulation of the inflammatory response. KEGG analysis indicated that urinary tract infections likely involve the TNF-αsignaling pathways. The 20 hub genes were selected from the protein-protein interaction network, and the highly significant hub genes were verified by animal experiments. Our findings provide potential targets for exploring new treatments for urinary tract infections. After a comprehensive analysis of the GEO database, these results may facilitate development of new diagnosis and treatment strategies for urinary tract infections.Entities:
Keywords: Differentially expressed gene; protein-protein interaction network; tissue-specific gene expression; urinary tract infection
Mesh:
Substances:
Year: 2021 PMID: 34592898 PMCID: PMC8806911 DOI: 10.1080/21655979.2021.1987081
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Figure 1.Flow chart of analyses performed in this research
Primers used in this study
| Gene | Forward Primer | Reverse Primer |
|---|---|---|
| TNF | TCCAGGCGGTGCCTATGT | GCCCCTGCCACAAGCA |
| IL-6 | CCACGGCCTTCCCTACTTC | TTGGGAGTGGTATCCTCTGTGA |
| IL-1β | AGTTGACGGACCCCAAAAGA | GGACAGCCCAGGTCAAAGG |
| GAPDH | CATGGCCTTCCGTGTTCCTA | GCGGCACGTCAGATCCA |
Figure 2.Heat maps of potential DEGs in the two microarray datasets (a) GSE43790 and (b) GSE124917
Figure 3.Volcano maps of the distributions of all DEGs in (a) GSE43790 and (b) GSE124917. Red, green, and gray colors respectively represent up-regulated genes, down-regulated genes, and genes with no difference in expression. Venn diagrams showing (c) 147 up-regulated DEGs and (d) 40 down-regulated genes common to both GSE43790 and GSE124917
Figure 4.Significant KEGG pathways (a) and GO terms (b) enriched with DEGs. The size of the bubble indicates the enrichment score, and the color indicates the significance of enrichment
GO and KEGG pathway enrichment analysis of the most important items in hub genes
| Category | Pathway ID | Pathway description | Count | P value |
|---|---|---|---|---|
| GO-BP | GO:0032496 | response to lipopolysaccharide | 29 | 2.95121E-24 |
| GO-BP | GO:0001817 | regulation of cytokine production | 31 | 1.69824E-15 |
| GO-BP | GO:0007159 | leukocyte cell-cell adhesion | 22 | 5.24807E-15 |
| GO-BP | GO:0031349 | positive regulation of defense response | 25 | 1.99526E-14 |
| GO-BP | GO:0050727 | regulation of inflammatory response | 24 | 1.25893E-13 |
| GO-CC | GO:0098552 | side of membrane | 17 | 7.58578E-07 |
| GO-CC | GO:0033256 | I-kappaB/NF-kappaB complex | 3 | 1.12202E-06 |
| GO-CC | GO:0048786 | presynaptic active zone | 5 | 9.54993E-05 |
| GO-CC | GO:0009898 | cytoplasmic side of plasma membrane | 6 | 0.000870964 |
| GO-CC | GO:0036464 | cytoplasmic ribonucleoprotein granule | 7 | 0.001 |
| GO-MF | GO:0005126 | cytokine receptor binding | 18 | 3.01995E-13 |
| GO-MF | GO:0051019 | mitogen-activated protein kinase binding | 5 | 2.81838E-06 |
| GO-MF | GO:0001228 | DNA-binding transcription activator activity,RNA polymerase II-specific | 13 | 9.12011E-06 |
| GO-MF | GO:0002020 | protease binding | 6 | 0.000245471 |
| GO-MF | GO:0001883 | purine nucleoside binding | 10 | 0.00025704 |
| KEGG-PATHWAY | hsa04668 | TNF signaling pathway | 28 | 3.16228E-36 |
| KEGG-PATHWAY | ko04621 | NOD-like receptor signaling pathway | 21 | 8.51138E-21 |
| KEGG-PATHWAY | ko04060 | Cytokine-cytokine receptor interaction | 21 | 1.28825E-16 |
| KEGG-PATHWAY | hsa05200 | Pathways in cancer | 24 | 8.51138E-13 |
| KEGG-PATHWAY | hsa04217 | necroptosis | 13 | 1.04713E-10 |
Figure 5.Hub genes in the TNF-α signaling pathway
Figure 6.Protein-protein interaction analysis and identification of hub genes. The STRING database-predicted interactions of the 187 up- and down-regulated DEGs shared between the two microarray datasets (a). The Cytoscape plug-in Network Analyzer was applied to analyze the data (b), followed by the Cytohubba plug-in to analyze hub genes to obtain the highest ranking genes (top 20 shown)
The most significant upregulated and downregulated genes in DEGs
| GSE43790 | GSE124917 | GSE43790 | GSE124917 | |||
|---|---|---|---|---|---|---|
| CXCL8 | Interleukin-8 | 4.37 | 5.37 | 2.63E-09 | 9.54E-08 | Upregulated |
| RELA | Transcription factor p65 | 1.27 | 2.25 | 7.33E-04 | 7.27E-06 | Upregulated |
| CXCL1 | Growth-regulated alpha protein | 4.88 | 5.73 | 1.85E-07 | 5.73E-05 | Upregulated |
| TNF | Tumor necrosis factor | 3.34 | 4.56 | 2.20E-06 | 1.37E-02 | Upregulated |
| NFKB1 | Nuclear factor NF-kappa-B p105 subunit | 1.53 | 2.01 | 4.27E-04 | 8.94E-06 | Upregulated |
| CXCL2 | C-X-C motif chemokine 2 | 3.76 | 5.98 | 7.24E-08 | 2.01E-06 | Upregulated |
| C3 | Complement C3 | 1.18 | 4.30 | 8.46E-03 | 1.45E-04 | Upregulated |
| SAA1 | Serum amyloid A-1 protein | 1.07 | 4.13 | 4.91E-03 | 3.86E-02 | Upregulated |
| CCL5 | C-C motif chemokine 5 | 1.39 | 10.65 | 1.60E-02 | 8.65E-07 | Upregulated |
| CXCL10 | C-X-C motif chemokine 10 | 3.66 | 14.04 | 7.13E-06 | 1.58E-08 | Upregulated |
| IL6 | Interleukin-6 | 4.01 | 3.79 | 6.15E-08 | 3.07E-05 | Upregulated |
| CCL20 | C-C motif chemokine 20 | 5.61 | 7.37 | 1.99E-07 | 4.61E-05 | Upregulated |
| IL1B | Interleukin-1 beta | 2.87 | 6.27 | 1.19E-04 | 2.93E-04 | Upregulated |
| BDKRB2 | B2 bradykinin receptor | 1.93 | 1.43 | 1.47E-05 | 3.41E-02 | Upregulated |
| GPER1 | G-protein coupled estrogen receptor 1 | −1.62 | −1.41 | 1.12E-02 | 3.57E-04 | Downregulated |
| S1PR5 | Sphingosine 1-phosphate receptor 5 | −1.78 | −1.98 | 6.58E-04 | 3.26E-02 | Downregulated |
| BDKRB1 | B1 bradykinin receptor | 3.09 | 3.53 | 1.45E-05 | 2.35E-05 | Upregulated |
| CX3CL1 | Fractalkine | 3.63 | 6.18 | 2.39E-05 | 2.34E-06 | Upregulated |
| BIRC3 | Baculoviral IAP repeat-containing protein 3 | 3.04 | 5.29 | 3.96E-09 | 5.30E-06 | Upregulated |
| ADORA1 | Adenosine receptor A1 | −1.02 | −1.06 | 9.53E-03 | 1.13E-02 | Downregulated |